Tumors become invasive by penetrating adjacent connective tissue, but the underlying biological mechanisms remain obscure. We recently identified a precise gene expression signature of fibroblastic origin associated with cancer invasion, the first step of the metastatic cascade. The signature contains many coordinately overexpressed genes, prominent among which are COL11A1, THBS2 and INHBA. Here we show that there is a striking similarity between the set of expressed genes in this metastasis-associated fibroblastic (MAF) signature and the set of genes that are downregulated when fibroblasts are reprogrammed to induced pluripotent stem cells (iPSCs). Because it is known that fibroblast reprogramming involves a mesenchymal-epithelial transition (MET), the above facts suggest that, conversely, the metastasis-associated fibroblasts responsible for the signature may result from stem-like cells undergoing some type of epithelial-mesenchymal transition (EMT). Therefore, we speculate that cancer stem cells (CSCs) undergoing some type of EMT become fibroblastic to obtain motility and invasiveness, reactivating early embryonic developmental pathways, and that these fibroblast-like cells are the main source of the MAF signature that we previously identified.
Introduction
We recently identified and reported [1] a precise gene expression signature consisting of a set of genes that are coordinately overexpressed only in samples of cancer that have exceeded a particular stage, specific to each cancer type (a previous version also available in Nature Precedings at http://hdl.handle.net/10101/npre.2010.4503.1). The same signature appears in solid cancer types, including pancreatic, ovarian, colon, prostate, breast, gastric, neuroblastoma and Ewing's sarcoma, the only exceptions that we found being blood and brain cancers.
Among the overexpressed genes are various collagens and proteinases, fibroblast activation protein, α-SMA, fibronectin and proteoglycans, suggesting a fibroblastic source. The signature, however, is not of a general fibroblastic nature, but instead has its own precise special characteristics, one of which is that genes COL11A1, THBS2 and INHBA have the most prominent presence. We identified collagen COL11A1 as a reliable proxy for the signature. In fact, in each rich cancer dataset, but not in non-cancer datasets, finding the list of genes whose expression is most correlated with that of COL11A1 consistently identifies the other genes of the signature as a result of the presence of those high-stage samples that contain it. The signature also contains several transcription factors associated with epithelial-mesenchymal transition (EMT), particularly slug (SNAI2). Notably, however, it does not contain snail (SNAI1), which we found, at least in ovarian cancer, to be methylated. Therefore, we have hypothesized that the signature corresponds to a biological mechanism leading to the presence of a particular type of fibroblasts, to which we refer as the "Metastasis Associated Fibroblasts" (MAFs), because cancer invasiveness is the first step of the metastatic cascade. Table 1 shows a list of the 64 genes corresponding to the 100 most overexpressed probe sets, as we previously reported [1] , of the signature, to which we refer as the "MAF signature."
To obtain clues about the origin and nature of the MAF signature, we compared it with other known signatures. Among all signatures that we searched outside cancer datasets, we found by far the largest enrichment to be present in the set of genes that are downregulated in induced pluripotent stem cells (iPSCs) as well as embryonic stem cells (ESCs) compared to the fibroblasts before reprogramming. The presence of the signature was most evident in several gene expression datasets comparing mouse embryonic fibroblasts (MEFs) reprogrammed into iPSCs.
Because it is known [2] that a mesenchymal-epithelial transition (MET) is part of the reprogramming of mouse fibroblasts into stem-like cells, we hypothesize that, conversely, the MAF signature is mainly produced by fibroblasts resulting, at least partly, from cancer stem cells (CSSs) undergoing some type of EMT and obtaining mesenchymal phenotype.
Results
Since the three genes COL11A1, THBS2, INHBA are required and prominent in the MAF signature, we performed Gene Set Enrichment Analysis in the Molecular Signature Database of the Broad Institute for these three genes. The search only revealed five sets containing all genes ( Table 2) . Consistent with the discovery of the MAF signature [1] , four of these sets correspond to genes upregulated in high-stage vs. low-stage cancer samples, specifically in lobular breast cancer, gastric cancer, ductal breast cancer, and papillary thyroid cancer. The fifth one included 514 genes downregulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 48 h time point that were not downregulated at the previous time point, 24 h. However, only nine of these 514 genes were among the 64 MAF genes of Table 1 .
Additional independent search yielded some other results. For example, we found that part of the signature is present in keloid lesions [3] , in which, however, THBS2 is interestingly shown to be downregulated, contrary to its prominent upregulation in the MAF signature.
The most remarkable similarity by far, however, was identified in a study analyzing the reprogramming of somatic cells to induced pluripotent stem cells [4] , where all three genes COL11A1, THBS2, INHBA, were mentioned in a list of genes found to be lower expressed in ES and iPS cells compared to mouse embryonic fibroblasts before reprogramming. Specifically, the section "Functional description of the genes lower expressed in ES and iPS cells compared to fibroblasts in mouse" in Supplementary text S1 mentions 22 among the top 64 MAF genes of We then downloaded and analyzed the seven datasets from mouse fibroblast reprogramming mentioned in [4] , as described in Materials and Methods, confirming the remarkable similarity of the differentially expressed genes with the MAF signature. Table 3 includes the 45 top-ranked genes that we identified, which includes 14 MAF genes from the 64 genes of Table 1  (P < 10 -27 ). Four of these 14 MAF genes (ASPN, LOXL2, CDH11, SERPINF1) are in addition to the list of 22 MAF genes mentioned above. The resulting heat maps for the 64 MAF genes of Table 1 for the seven datasets are shown in Figures 1a-1g .
Discussion
The parallels between embryonic development and tumor progression involving EMT have been well recognized [5] . On the other hand, recent research suggests that cell "stemness" and the ability to shift between epithelial and mesenchymal characteristics (probably in a continuous rather than abrupt manner) are qualities that appear to be closely related. For example, EMT generates cells with properties of stem cells [6] . Conversely, MET is involved in the reprogramming of fibroblasts into stem cells [2] . Therefore, our hypothesis, based purely on computational analysis, is consistent with the notion that cancer stem cells with mesenchymal characteristics, derived from cancer cells poised to undergo EMT, obtain metastatic potential [7] .
We speculate that these fibroblastic cells (MAFs) originate from the primary tumor rather than the stroma and constitute the main source of the MAF signature. They could be triggered from contextual reactive stroma microenvironmental signals, and they would open passageways perhaps allowing for other cancer cells to also go through the adjacent connective tissue.
Furthermore, because the MAF signature is observed even in non-epithelial cancers, such as neuroblastoma [1] , the above hypothesis would imply the employment of a mesenchymal transition mechanism more general than what EMT is assumed to be. Many among the top MAF genes have previously been individually identified as associated with metastatic potential in cancer. If our hypothesis is correct, such associations can largely be explained by the fact that these genes are expressed by the cancer cells themselves after they have obtained mesenchymal phenotype and become invasive.
Materials and Methods

Gene Expression Data
The gene expression datasets were downloaded from Gene Expression Omnibus under accession ID GSE7815 [8] , GSE7841 [9] , GSE8024 [10] , GSE13211 [11] , GSE13770 [12] , GSE14012 [13] , GSE15267 [14] . The expression data were normalized as provided by the original author. We applied base-2 logarithm to the expression value if the dataset values were not log-transformed.
Differential Expression Analysis
The differentially expressed genes were identified by the limma package in R. We applied linear model and empirical Bayesian methods on the probe-level data, then taking the minimum of the P values of all probes corresponding to the same genes as the gene's P value for differently expression. Since we are only interested in genes that are overexpressed in fibroblasts, we only computed the upper-tail P value in the fibroblast vs. ESC or iPSC comparisons.
After obtaining the P values of each gene in each datasets, we simply take the log 10 -average of the P values across datasets as the scores for overexpression for the gene across each datasets. We then rank the scores and Table 3 shows the top 45 entries.
Data Visualization
We first collapsed the probe-level expression data into gene-level using the median of the probes corresponding to the same gene. Then we extracted the 64 MAF genes of Table 1 existing in the dataset to create heatmaps using GenePattern [15] . The column is clustered using pairwise average-linkage, with Euclidean distance as column distance measure. 
